DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES
Primary Purpose
Mitochondrial Diseases
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
samples
Sponsored by
About this trial
This is an interventional basic science trial for Mitochondrial Diseases
Eligibility Criteria
Inclusion Criteria:
- general criteria: major or minor patients, sporadic or isolated cases
- criteria related to pathology:
- Suspected mitochondrial pathology which will be evaluated according to the following criteria (expertise of the clinician of the MM reference center):
Clinical picture suggestive of a mitochondrial pathology ("illegitimate association" of symptoms, specific syndrome of MELAS type for example, muscular deficit, ptosis ...) AND / OR
- Metabolic assessment suggestive of respiratory tract involvement AND / OR
- Identification of a deficiency involving one or more complexes of the respiratory chain from a muscular specimen
- Presence on the histological analysis of the muscle biopsy of COX-negative fibers
- signing of informed consent for minor patients signed by at least one of the parents or the representative of the parental authority
Exclusion Criteria:
- Persons deprived of their liberty by a judicial or administrative decision;
- Persons hospitalized without consent;
- Persons admitted to a health or social institution for purposes other than research;
- Persons of legal age who are under protection or who are unable to express their consent. Inability to co-operate.
Sites / Locations
- CHU de NiceRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
biological samples
Arm Description
biological samples on patients with MITOCHONDRIAL DISEASES
Outcomes
Primary Outcome Measures
number of amplification with the NGS technique
Secondary Outcome Measures
comparaison of the number of amplification between NGS technique and the PCR-RFLP technique
Full Information
NCT ID
NCT03216252
First Posted
July 7, 2017
Last Updated
July 23, 2018
Sponsor
Centre Hospitalier Universitaire de Nice
1. Study Identification
Unique Protocol Identification Number
NCT03216252
Brief Title
DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES
Official Title
IMPLEMENTING A SINGLE MUSCLE FIBER DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL FOR THE VARIANTS OF UNKNOWN SERVICE IN MITOCHONDRIAL DISEASES
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
February 2, 2018 (Actual)
Primary Completion Date
July 2019 (Anticipated)
Study Completion Date
July 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
2622/5000 Mitochondrial diseases (MM) are the most common metabolic diseases. Since these pathologies are very heterogeneous in clinical terms, only the identification of mutations in nuclear genes or mitochondrial DNA confirms the diagnosis.
The full-scale study of mtDNA by high-throughput sequencing (NGS) is a first step in the diagnostic approach. The recent introduction of this revolutionary new technology has greatly increased the efficiency of mutation identification. However, in addition to known pathogenic mutations, NGS reveals numerous variants whose significance is currently unknown. A major challenge to obtain a reliable diagnosis is therefore the interpretation of the clinical impact of these new rare variants which proves to be very difficult.
Pathogenicity criteria allow the classification of variants from benign to pathogenic. One of the major pathogenicity criteria is a good correlation of heteroplasmic level with tissue or cellular involvement. Indeed, mtDNA mutations are generally heteroplasmic, which corresponds to the coexistence of normal and mutated molecules in the same cell or tissue, the most affected tissues having a high rate of mutation. On a muscle biopsy of an affected patient, the fibers often present an enzyme deficiency in cytochrome c oxidase (COX-negative) which can be demonstrated in immunohistochemistry. The single fiber study allows to isolate the deficient fibers and to quantify the heteroplasmic rate of a variant. The presence of a high level of heteroplasm in the COX-negative fibers, unlike fibers without deficit, is a strong argument in favor of the pathogenicity of this variant. Currently, this technique is not used routinely in diagnostic laboratories but only occasionally in a research framework in some laboratories. It is a heavy technique that consists of a first stage of laser microdissection of the various muscle fibers followed by a second step of quantification of the variant from each fiber. This second step requires a specific focus for each identified variant.
The aim of this pilot study is to develop a new technique for quantification of single-fiber heteroplasmics isolated by NGS laser microdissection. This, independent of the type of variant, will avoid the long and costly adjustments required for each new variant identified and thus facilitate its use
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mitochondrial Diseases
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
biological samples
Arm Type
Other
Arm Description
biological samples on patients with MITOCHONDRIAL DISEASES
Intervention Type
Biological
Intervention Name(s)
samples
Intervention Description
Blood samples, oral smear and urine
Primary Outcome Measure Information:
Title
number of amplification with the NGS technique
Time Frame
36 months
Secondary Outcome Measure Information:
Title
comparaison of the number of amplification between NGS technique and the PCR-RFLP technique
Time Frame
36 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
general criteria: major or minor patients, sporadic or isolated cases
criteria related to pathology:
Suspected mitochondrial pathology which will be evaluated according to the following criteria (expertise of the clinician of the MM reference center):
Clinical picture suggestive of a mitochondrial pathology ("illegitimate association" of symptoms, specific syndrome of MELAS type for example, muscular deficit, ptosis ...) AND / OR
Metabolic assessment suggestive of respiratory tract involvement AND / OR
Identification of a deficiency involving one or more complexes of the respiratory chain from a muscular specimen
Presence on the histological analysis of the muscle biopsy of COX-negative fibers
signing of informed consent for minor patients signed by at least one of the parents or the representative of the parental authority
Exclusion Criteria:
Persons deprived of their liberty by a judicial or administrative decision;
Persons hospitalized without consent;
Persons admitted to a health or social institution for purposes other than research;
Persons of legal age who are under protection or who are unable to express their consent. Inability to co-operate.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cécile ROUZIER
Phone
33 4 92 03 62 43
Email
rouzier.c@chu-nice.fr
Facility Information:
Facility Name
CHU de Nice
City
Nice
ZIP/Postal Code
06200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rouzier cecile
Email
rouzier.c@chu-nice.fr
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES
We'll reach out to this number within 24 hrs